Metabolic Response to Pegylated Arginine Deiminase in Mesothelioma With Promoter Methylation of Argininosuccinate Synthetase

Novel Mechanistic Insights into Arginine Deiminase Pharmacology Suggest 18F-FDG Is Not Suitable to Evaluate Clinical Response in Melanoma

(2012) L. Stelter et al.   JOURNAL OF NUCLEAR MEDICINE

Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy

(2011) Everett Stone et al.   JOURNAL OF CONTROLLED RELEASE

Phase II Study of Pegylated Arginine Deiminase for Nonresectable and Metastatic Hepatocellular Carcinoma

(2010) Evan S. Glazer et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastrosplenic Fistula From Hodgkin's Lymphoma

(2009) Carolyn D. Seib et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1 /Sp4

(2009) W.-B. Tsai et al.   MOLECULAR CANCER THERAPEUTICS

Arginine Deprivation as a Targeted Therapy for Cancer

(2008) L. Feun et al.   CURRENT PHARMACEUTICAL DESIGN

Advances in the systemic therapy of malignant pleural mesothelioma

(2008) Dean A Fennell et al.   Nature clinical practice. Oncology